Last updated: 2026-10-16 22:25:40. Prices reflect the latest after-hours trading data. Stock price data is sourced from Massive.
Arcturus Therapeutics Holdings Inc. (ARCT) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $10.35, with a market capitalization of $316.06M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $5.50 to $24.17. This page covers its latest market performance, valuation, price trends and company information.
$316.06M | |
$11.16 | |
$129.71 | |
$4.11 | |
$11.27 | |
683.51K | |
944.37K | |
-- | |
$24.17 | |
$5.50 | |
-- | |
-- |
Arcturus Therapeutics Holdings Inc. (ARCT) is trading at $10.45 in after-hours trading as of 2026-10-16 22:15:00, down 7.28% ($0.82) from the regular-session close of $11.27.
After-hours trading shows how investors are pricing ARCT after the regular session closes. The current after-hours price is below the regular-session close, indicating cautious after-hours sentiment.
Over the past seven days, Arcturus Therapeutics Holdings Inc. (ARCT) moved from $12.77 to $10.35, representing a decline of 18.93% ($2.42).
The stock traded between $10.26 and $14.32 during the period. The latest price is near the lower end of the 7-day range, indicating strong downward.
The average daily volume was 548.26 thousand shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 26.0%
ARCT is currently trading at $10.35, placing it 26.0% of the way from its 52-week low of $5.50 to its 52-week high of $24.17. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Arcturus Therapeutics Holdings Inc is an RNA medicines company focused on the development of infectious disease vaccines and opportunities within liver and respiratory rare diseases. It operates in one business segment, which includes all activities related to the discovery, development, and commercialization of messenger RNA medicines. The company's pipeline includes LUNAR-OTC and LUNAR-CF. Its Vaccine candidates include LUNAR-FLU, KOSTAIVE XBB.1.5, KOSTAIVE, and Others.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 111 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Arcturus Therapeutics Holdings Inc. (ARCT) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.